Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."
|Articles|September 21, 2021
OM Pharma Wins Geneva Economy Award
Advertisement
OM Pharma, a Geneva, Switzerland-based biopharmaceutical company, active in the prevention of recurrent respiratory and urinary tract infections and the treatment of vascular diseases has won the 2021 Geneva Economy Award.
The Geneva Economy and Innovation Awards, created in 2012, aim to honor companies whose reputation and influence convey a positive and dynamic image of Geneva.
The independent jury noted OM Pharma’s economic and social policy. Aiming at the long-term development of the company, all its profits are reinvested in research and development (R&D) and the expansion of its Geneva site.
OM Pharma is a private company founded in Geneva in 1937. The company employs a total of 400 people, including 300 in Geneva and 40 in Fribourg.
Advertisement
Related to this article
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.
Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.
Advertisement
Advertisement